Billionaire Ken Griffin Just Loaded Up on This Dividend King, and Wall Street Still Sees Upside
Key PointsKen Griffin's Citadel increased its AbbVie stake by over 500% in the second quarter of 2026.
Wall Street analysts often monitor the investment patterns of seasoned investors like Ken Griffin, the founder of hedge fund Citadel. By studying such investors' actions, one can glean potential insights for one's own portfolio. The comprehensive 13F filing submitted by Griffin's Citadel serves as a valuable source of information.
The latest filing reveals a substantial investment in AbbVie (NYSE: ABBV), marking a 500% increase in his stake. Here's a closer look at Griffin's rationale and why his move may be worth emulating.
Despite the turbulence stemming from various geopolitical tensions, persistent high inflation, and the looming risk of excessive leverage, the stock market finds itself at an all-time high. According to Jamie Dimon, CEO of JPMorgan Chase (NYSE: JPM), these formidable challenges could coalesce, leading to significant market disruptions. Griffin's decision to invest in AbbVie, however, suggests a bullish outlook on the healthcare sector, given its reputation for resilience.
AbbVie, a prominent player in the healthcare industry, emerges as a defensive stock in Griffin's portfolio. Its robust position in the defensive space aligns with the sector's inherent resilience, as healthcare remains an indispensable necessity.
Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
